EGFR and erythema multiforme: Other selected cutaneous AEs, such as erythema multiform, maculopapular rash, and skin exfoliation, were more frequent among anti-PD-1/L1 plus VEGFR/EGFR inhibitor combination therapy than other ICI combination regimens and required more attention from oncologists and dermatologists.